Arcellx (ACLX) Expected to Announce Earnings on Thursday

Arcellx (NASDAQ:ACLX) is projected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Arcellx to post earnings of ($1.01) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Arcellx Trading Down 1.7%

Shares of NASDAQ:ACLX opened at $69.04 on Thursday. Arcellx has a twelve month low of $47.86 and a twelve month high of $94.07. The firm has a 50 day simple moving average of $67.26 and a 200-day simple moving average of $74.84. The company has a market capitalization of $3.99 billion, a PE ratio of -17.57 and a beta of 0.36.

Insider Buying and Selling

In other news, insider Christopher Heery sold 5,882 shares of the stock in a transaction that occurred on Wednesday, January 14th. The shares were sold at an average price of $68.51, for a total value of $402,975.82. Following the completion of the sale, the insider directly owned 23,749 shares of the company’s stock, valued at $1,627,043.99. This represents a 19.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders sold 19,450 shares of company stock worth $1,283,477. Company insiders own 8.35% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Mercer Global Advisors Inc. ADV boosted its position in Arcellx by 19.0% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 4,107 shares of the company’s stock worth $268,000 after purchasing an additional 655 shares during the period. XTX Topco Ltd acquired a new stake in shares of Arcellx during the 4th quarter worth about $4,732,000. Vestal Point Capital LP increased its stake in shares of Arcellx by 134.0% in the fourth quarter. Vestal Point Capital LP now owns 2,925,000 shares of the company’s stock valued at $190,710,000 after buying an additional 1,675,000 shares in the last quarter. Virtus Investment Advisers LLC raised its stake in shares of Arcellx by 116.3% in the fourth quarter. Virtus Investment Advisers LLC now owns 3,701 shares of the company’s stock worth $241,000 after acquiring an additional 1,990 shares during the last quarter. Finally, Tudor Investment Corp ET AL bought a new stake in Arcellx during the 4th quarter worth about $3,001,000. Institutional investors own 96.03% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ACLX shares. Wolfe Research started coverage on Arcellx in a research report on Tuesday, November 18th. They issued a “peer perform” rating on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $105.00 price objective on shares of Arcellx in a research note on Thursday, February 5th. Canaccord Genuity Group restated a “buy” rating and set a $130.00 target price on shares of Arcellx in a report on Monday, December 8th. HC Wainwright restated a “buy” rating and set a $115.00 target price on shares of Arcellx in a research note on Wednesday, February 4th. Finally, Guggenheim restated a “buy” rating on shares of Arcellx in a research note on Monday, November 24th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $109.20.

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.